<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674141</url>
  </required_header>
  <id_info>
    <org_study_id>MS089-HMO-CTIL</org_study_id>
    <nct_id>NCT00674141</nct_id>
  </id_info>
  <brief_title>Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment</brief_title>
  <official_title>Nasal Administration of Dexamethasone for MS Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in
      relapsing MS patients
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    was not approved by the ministry of health
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">January 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in the EDSS functional system score</measure>
    <time_frame>four months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>MS Patient With Relpasing Remitting Attacks</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>only one experimental treated group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone soduim phosphate</intervention_name>
    <description>nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MS patients with esatblished relapsing remitting attacks

          -  increase in EDSS of at least 1 point for a least one day

        Exclusion Criteria:

          -  children under 18

          -  pregnant patients

          -  patients with diabetes

          -  known allergy to steroids

          -  patients who received steroids within 3 months prior to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elka Touitou, PhD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebrew University, Jerusalem. Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <last_update_submitted>June 2, 2010</last_update_submitted>
  <last_update_submitted_qc>June 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dminitrios Karussis</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <keyword>Multiple Sclerosis, relapsing remitting, Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

